Viewpoints on Managing DR: Addressing Moderate-to-Severe NPDR

Published: Sept. 15, 2019, 4 a.m.

Guest: David M. Brown, MD, FACS
Guest: Rishi P. Singh, MD

Even though the prevalence of diabetes continues to rise globally, the good news is that there are emerging treatment options for diabetic eye diseases like nonproliferative diabetic retinopathy. Join Dr. David Brown and Dr. Rishi Singh as they review the recent evidence behind one of these options: anti-VEGF inhibitors.

Vision loss caused by diabetic retinopathy can have a significant impact on a patient's quality of life. This activity emphasizes more assertive action in clinical practice for patient with diabetes. The acronym ASSERT-D is a reminder to Assess and Screen for Eye health and Refer or Treat patients with Diabetes.